PVI
NTLA icon

Pura Vida Investments’s Intellia Therapeutics NTLA Stock Holding History

Pura Vida Investments’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100,300
Closed -$5.61M – 230
2022
Q3 		$5.61M Sell
100,300
-94,500
-49% -$5.86M 0.32% 76
2022
Q2 		$10.1M Buy
+194,800
New +$9.89M 0.59% 47
2021
Q3 		– Sell
-246,900
Closed -$40M – 315
2021
Q2 		$40M Buy
+246,900
New +$19.2M 1.24% 15

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Pura Vida Investments's NTLA Position: Q2 2022 in Review

Pura Vida Investments sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 104,073 shares — an estimated $5.28M sold.

Pura Vida Investments first reported a position in NTLA in Q1 2021 and held it in 5 quarters. The position peaked at $34.8M in Q2 2021. 300 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Pura Vida Investments reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Pura Vida Investments sold 104,073 Intellia Therapeutics shares in Q2 2022, an estimated $5.28M.
  • Pura Vida Investments first reported a position in Intellia Therapeutics in Q1 2021 and held it in 5 quarters.
  • Pura Vida Investments's Intellia Therapeutics position peaked at $34.8M in Q2 2021.
  • 300 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.